RBC trims Healthpeak's target, still likes the stock

Same love, slightly less optimism

RBC Capital’s Michael Carroll isn’t bailing on Healthpeak Properties — he’s still got a Buy rating on the healthcare REIT. But he did nudge the price target down from $21 to $20, which is analyst-speak for: “still good, just not quite as good as I thought yesterday.”

Why you should care

For a stock like Healthpeak, target-price cuts can matter because REITs are all about expectations. If rates, occupancy, or funding costs start acting like that one friend who always says “I’m five minutes away” and never shows up, valuation math gets messy fast. A lower target doesn’t scream trouble, but it does hint at a slightly more cautious view on near-term upside.

The investor takeaway

Here’s the vibe:

• Rating stays positive: RBC still thinks the shares are worth owning.
• Target goes lower: upside is now a bit more limited.
• The stock still has analyst support: this is a trim, not a flip to bearish.

Big picture: when a Buy stays a Buy, the market usually hears “calm down, not panic.” It’s not the kind of note that rewrites the story — just one that adjusts the fine print.